[Skip to Content]
[Skip to Content Landing]
Views 341
Citations 0
Editor's Note
July 24, 2019

Regional Differences in Secondary Prevention Therapy—Geography Should Not Be Destiny

Author Affiliations
  • 1Duke Clinical Research Institute, Durham, North Carolina
  • 2Associate Editor, JAMA Cardiology
  • 3Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles Medical Center, Los Angeles
  • 4Section Editor, JAMA Cardiology
JAMA Cardiol. Published online July 24, 2019. doi:10.1001/jamacardio.2019.2548

Statin therapy is a cornerstone of secondary prevention in adults with atherosclerotic cardiovascular disease; it reduces the risk of subsequent myocardial infarction, stroke, revascularization, and cardiovascular death. Because of their greater efficacy compared with moderate-intensity statins,1 high-intensity statins received a class I recommendation for adults 75 years and younger with atherosclerotic cardiovascular disease in the 2013 American College of Cardiology/American Heart Association cholesterol guidelines.